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1  | INTRODUC TION
Progressive multifocal leukoencephalopathy (PML) is a demyelin-
ating central nervous system (CNS) disorder caused by reactiva-
tion of the John Cunningham (JC) virus in the setting of immune 
suppression. Progressive multifocal leukoencephalopathy was first 
described in patients with hematological malignancies1 but became 
better recognized in the 1980s during the acquired immunodefi-
ciency syndrome (AIDS) epidemic. Iatrogenic immunosuppression 
(particularly the monoclonal antibody natalizumab), solid organ 
transplantation (SOT), and hematopoietic cell transplantation 
(HCT) are also established risk factors.2-4 Reversal of the patient's 
underlying immune deficiency can lead to a paradoxical clinical 
worsening called the immune reconstitution inflammatory syn-
drome (IRIS), which is characterized by severe inflammation and 
marked CNS infiltration with cytotoxic T cells.4-6 PML-IRIS can 
conceivably occur in SOT recipients whose immunosuppression is 
reduced but has been scarcely reported in this setting. Additionally, 
data on the outcomes and management of PML-IRIS among SOT 
recipients are sparse.2 Herein, we present a case of a patient with 
PML after kidney transplant who developed severe IRIS during her 
treatment course. We highlight the diagnostic workup obtained, in-
cluding a thallium SPECT scan and brain biopsy, and review the lit-
erature on PML and PML-IRIS, their diagnosis, and their treatments 
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Abstract
Progressive multifocal leukoencephalopathy (PML) is a life-threatening central nerv-
ous system (CNS) disorder, most commonly described in patients infected with the 
human immunodeficiency virus (HIV). Limited data exist on its natural history and 
treatment in solid organ transplant (SOT) recipients. A complication of PML is the 
immune reconstitution inflammatory syndrome (IRIS), which develops after T cell re-
constitution and can have severe consequences when it occurs in the CNS. While well 
described in HIV-infected individuals, its clinical features, diagnosis, and treatment 
after SOT are largely unknown. We report a case of a kidney transplant recipient 
who was diagnosed with PML and developed significant worsening of her symptoms 
upon reduction of immunosuppression. Thallium SPECT showed avid uptake sugges-
tive of lymphoma, but the diagnosis of PML-IRIS was ultimately established by brain 
biopsy. She survived with nearly complete restoration of her functional status after 
a prolonged steroid taper.
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in SOT. We also comment on the utility of SPECT scans in distin-
guishing PML and PML-IRIS from CNS malignancies.
2  | C A SE PRESENTATION
The patient was a 60-year-old woman with a history of deceased 
donor renal transplant performed for IgA nephropathy 9 years 
prior to presentation. She received alemtuzumab induction. She 
had no infectious complications or recent immunosuppression aug-
mentation for rejection. Her transplant-related medications at the 
time of evaluation were tacrolimus, mycophenolate mofetil, and 
trimethoprim-sulfamethoxazole.
She presented with 2 months of progressively worsening word-
finding difficulty, specifically with the inability to name familiar 
places and objects (Figure 1). She denied any effect on other cogni-
tive domains. However, on bedside evaluation she had compromised 
executive functioning (unable to perform trails assessment), atten-
tion (could repeat numbers forward but not backward), language 
(unable to repeat sentences, difficulty with naming), and delayed 
recall (named zero of five objects at five minutes). At that time, her 
strength, sensation, and coordination were preserved. Serum creat-
inine was 2.3 mg/dL, around her baseline. She had mild leukopenia 
and lymphopenia with a white blood cell count of 2900 cells/L and 
an absolute lymphocyte count of around 600 cells/L, both at her 
baseline. The rest of her laboratory tests were unremarkable.
Non-contrasted magnetic resonance imaging (MRI) of the brain 
identified multifocal T2 signal hyperintensities in the left posterior tem-
poral and parietal lobes, cingulate gyrus, and splenium of the corpus 
callosum (Figure 2). There was minimal associated mass effect and no 
areas of restricted diffusion. She subsequently had cerebrospinal fluid 
(CSF) analysis, which was notable for one white blood cell per high-
power field, zero red blood cells, glucose of 91 mg/dL (serum 68 mg/
dL), and protein of 46 g/dL. Cerebrospinal fluid JC virus polymerase 
chain reaction (PCR) was positive, but at <10 copies/mL. Cerebrospinal 
fluid cytology was negative for malignant cells. Human immunodefi-
ciency virus (HIV) and Epstein-Barr virus (EBV) testing were negative.
She was diagnosed with PML and was initially managed by discon-
tinuation of mycophenolate alone (Figure 1). After further discussion 
with the patient and her family, the decision was made to slowly wean 
tacrolimus as a potentially lifesaving measure, knowing that this would 
likely lead to rejection of her allograft. Approximately 5 weeks later, 
tacrolimus was discontinued entirely. She was started on mirtazapine 
15 mg daily, based on limited case reports of its possible utility among 
patients with PML, including our own experience with a lung transplant 
recipient from our institution who received this drug and improved.7,8
Around this time, she developed significant worsening of her lan-
guage skills and had new symptoms of motor weakness and unsteady 
F I G U R E  1   Timeline of events; IRIS, 
immune reconstitution inflammatory 
syndrome; MMF, mycophenolate 
mofetil; PML, progressive multifocal 
leukoencephalopathy
F I G U R E  2   Initial brain MRI without 
contrast. Sequences shown are T2 FLAIR 
images, demonstrating hyperintensities in 
the left temporal and parietal lobes and in 
the splenium of the corpus callosum
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gait (Figure 1). She deteriorated further, with right hemiparesis, inabil-
ity to walk, unintelligible speech, and progressive cognitive deficits 
including an inability to follow simple commands. Mirtazapine was ini-
tially decreased to 7.5 mg due to sedation and then ultimately stopped 
about 1 month after its initiation. A brain MRI without contrast showed 
progression of T2 white matter signal change in the existing areas and 
new areas involving the right temporal lobe, right insula, and left sub-
thalamic nucleus (Figure 3). Contrast imaging was not obtained due to 
the risk of nephrogenic systemic fibrosis, at the recommendation of the 
transplant nephrology team. Differential diagnosis at the time included 
worsening of PML, development of IRIS, or an alternative diagnosis 
such as CNS post-transplant lymphoproliferative disorder (PTLD).
Based on literature demonstrating the potential utility of thal-
lium imaging in differentiating PML from CNS lymphoma among 
HIV-infected patients,9 a thallium SPECT scan was performed. 
This revealed increased thallium uptake in her known white matter 
lesions, suggesting the presence neoplastic process such as PTLD 
rather than PML (Figure 4). However, her subsequent CSF had a 
higher JC virus copy count (29 copies/mL). Ultimately, a biopsy of 
the left frontal lesion was performed and showed foci of demy-
elination, oligodendrocytes with enlarged nuclei containing viral 
inclusions, and reactive, bizarre-appearing astrocytes. The viral in-
clusions were positive for the JC virus by in situ hybridization (ISH), 
confirming the diagnosis of PML (Figure 5). Additionally, histology 
revealed a T cell and plasma cell inflammatory response, consistent 
with IRIS (Figure 6). She was treated with a prolonged oral steroid 
taper for IRIS, starting with 4 mg every 6 hours of dexametha-
sone (2 days), followed by an 11-week prednisone taper as follows: 
60 mg daily for 1 week, followed by 55 mg daily for 1 week, 50 mg 
daily for 1 week, 45 mg daily for 1 week, 35 mg daily for 3 weeks, 
25 mg daily for 2 weeks, and finally 15 mg daily for 2 weeks. After 
this, her prednisone dose was reduced to 5 mg daily, on which she 
remains in order to avoid allograft inflammation (Figure 1). Three 
months later, she was able to walk independently and had regained 
much of her language fluency. Interval MRI showed improvement 
in the white matter abnormalities. She resumed hemodialysis 
around 1 year after her initial diagnosis with PML. As of the writ-
ing of this manuscript, it has been nearly 2 years since she first 
presented. She is currently doing well and is nearly neurologically 
intact, with minimal residual speech impairment.
3  | DISCUSSION
Progressive multifocal leukoencephalopathy is uncommon in trans-
plant recipients but is associated with a poor prognosis. The largest 
F I G U R E  3   Follow-up brain MRI 
without contrast after clinical worsening. 
Sequences shows are T2 FLAIR, 
demonstrating interval progression of 
hyperintensities now with mass effect and 
spread to new brain regions
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study of PML after transplantation was a 2011 multicenter review 
of 69 patients, of whom 64% (44/69) were SOT recipients.2 Kidney 
transplants were the most common (n = 22), followed by liver 
(n = 10), lung (n = 6), and heart transplants (n = 6). All patients were 
diagnosed either by brain biopsy, CSF JC virus PCR, or autopsy. The 
median time to development of PML symptoms following transplan-
tation was 17 months but ranged widely from <1 month to more than 
20 years. Interestingly however, the hazard ratio of developing PML 
after SOT was greatest in the immediate post-transplant period, sug-
gesting that heightened immunosuppression from recent antibody 
induction and generally higher troughs of calcineurin inhibitors and 
high doses of antiproliferative agents may confer an increased risk of 
reactivation early after transplant.2 Nonetheless, later cases can also 
occur even without any immunosuppression augmentation, such as 
the case with our patient. The median time from symptom onset 
to death after SOT was 6.4 months after SOT (range < 1 month to 
>37 months), and the overall fatality rate was 84%.2 As is the case 
with HIV-infected individuals, the most common presenting symp-
toms were cognitive deficits, followed by weakness, visual distur-
bances, gait disorders, personality changes, aphasia, and seizures.
Elimination of iatrogenic immunosuppression remains the main-
stay of treatment after transplantation, though this may lead to graft 
loss. While graft failure is fatal in patients with life-sustaining organ 
transplants such as lungs, livers, and hearts, kidney transplant recip-
ients have the option of resuming dialysis. Nonetheless, data on the 
management of PML after SOT are largely derived from case series and 
case reports. In the aforementioned study,2 55% (24/44) of SOT recip-
ients received some form of treatment for PML. Of these 24 patients, 
79% (19/24) had their immunosuppression reduced, either as the sole 
intervention (n = 9) or in combination with adjunctive medical therapy 
(n = 10). Medications given to SOT recipients with PML included cytar-
abine (n = 8), mirtazapine (n = 4), cidofovir (n = 2), mefloquine (n = 2), 
interferon-alpha (n = 1), ganciclovir (n = 1), and the antiviral agent ti-
lorone (n = 1), either alone or in combination. Despite these efforts, 
no intervention had any clear impact on prognosis or survival. In more 
contemporary case reports, reduction of immunosuppression contin-
ues to be the most common treatment modality,10-12 though mirtazap-
ine was successfully used in one case of a lung transplant recipient.8
Mirtazapine, which inhibits JC virus cell entry by blocking the 
JC virus serotonin receptor 5HT2a, was successfully used in four 
HIV-infected individuals with PML,7 though its contribution to their 
clinical improvement is unclear as all four patients were also receiv-
ing antiretroviral therapy (ART). In addition, while a lung transplant 
recipient with JC virus encephalopathy improved with mirtazapine,8 
her MMF was also discontinued, and mirtazapine was eventually 
stopped due to drowsiness. Despite these potentially promising 
case reports, a 2016 meta-analysis of five cohort studies and 74 case 
reports (with only seven SOT recipients identified) found that mir-
tazapine had no effect on clinical outcome, which was largely driven 
by the presence of immunosuppression, hematological malignancy, 
or transplant.13 Nonetheless, the dismal prognosis of PML and the 
generally benign safety profile of mirtazapine prompted us to ad-
minister it to our patient as adjunctive treatment, though it did not 
lead to any clinical improvement and in fact may have contributed to 
increased somnolence when she developed IRIS.
Due to the absence of any effective antiviral agent to treat 
JC virus infections, there has been immense interest in the use of 
F I G U R E  4   Thallium SPECT showing increased thallium uptake in 
regions corresponding to abnormalities on prior MRI
F I G U R E  5   Hematoxylin and eosin 
(H&E) stained section shows an 
oligodendrocyte with an enlarged nucleus 
containing a viral inclusion (arrow) in a 
demyelinated area containing reactive 
astrocytes (original magnification ×400). 
A JC virus in situ hybridization (ISH) study 
shows scattered positive nuclei (original 
magnification ×400)
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immunomodulatory therapy for the treatment of PML. For instance, 
interleukin-7 in combination with a JC virus capsid vaccine resulted 
in CSF JC viral load clearance, MRI improvement, and clinical stabi-
lization of two patients with primary or acquired CD4 lymphopenia, 
though neither of these agents are readily available, and their ben-
efit remains speculative.14 One potential drug target is programmed 
cell death protein 1 (PD-1), which is a negative regulator of the 
immune response that is upregulated on CD4+ and CD8+ cells in 
patients with PML, and which may contribute to impaired JC viral 
clearance.15 In a recent study of eight patients with PML (four with 
hematological malignancies, two with HIV, and two with idiopathic 
lymphopenia) treated with the PD-1 inhibitor pembrolizumab, five 
patients had varying degrees of clinical, virological, and radiographic 
improvement or stabilization, which correlated with the emergence 
of a strong anti-JC virus cell-mediated immune responses.15 One pa-
tient had already improved prior to receiving pembrolizumab, and 
two (one with idiopathic lymphopenia and one with non-Hodgkin's 
lymphoma) deteriorated despite receiving it. No patient in this co-
hort developed IRIS. Larger randomized trials are required to de-
termine the effect of pembrolizumab on the natural history and 
prognosis of PML.
Allogeneic adoptive JC virus-specific T cell transfer is another 
emerging treatment modality. In a recent small study, investigators 
administered third-party, closely HLA-matched BK-virus-specific T 
cells to three patients with PML (one with a cord blood transplant, 
one with myeloproliferative disorder, and one with advanced HIV).16 
Results were mixed, with one patient achieving complete clinical, 
radiographic, and virological remission, and two only achieving a 
partial response. In addition, one of these patients had virological 
improvement but clinical deterioration and was thus transitioned to 
hospice. The latter two patients developed IRIS, which was thought 
to have been directly mediated by the virus-specific T cells. Larger 
studies are clearly needed to confirm the efficacy of this approach 
and to ascertain the true incidence and consequences of IRIS with 
adoptive T cell transfer. In addition, certain challenges related to the 
development of adoptive T cell therapies (eg, donor availability, HLA 
matching, and product generation time) must be overcome for such 
a treatment modality to become commonplace.17 A clinical trial of 
adoptive T cell therapy for PML is underway (NCT02694783).
Diagnostic evaluation of PML includes neuroimaging and CSF 
analysis for the detection of JC virus DNA, though large studies of 
the performance of the JC virus CSF PCR among SOT recipients have 
not been performed. Studies of HIV-infected individuals with PML 
have shown that PCR has a sensitivity and specificity of 72%-92% 
and 92%-100%, respectively.18-23 However, PCR is less sensitive in 
patients receiving ART vs those who are ART naïve (59% vs 90% sen-
sitivity, respectively), which is thought to be a marker of heightened 
immune reconstitution among persons on ART, resulting in reduced 
JC viral replication.24 Our patient had an extremely low initial CSF 
JC virus copy count of <10 copies/mL. Indeed, the CSF viral load 
can vary widely, from 102 copies/mL to >107 copies/mL,24 though 
more pronounced extremes have also been described. For instance, 
in one study of 28 patients with natalizumab-associated PML, 50% 
of patients had CSF JC virus viral loads of <500 copies/mL when 
performed by a commercial assay,25 with a median of 62.5 copies/
mL (range 0-500 copies/mL). Furthermore, CSF JC viral loads were 
markedly different when performed using a more sensitive assay at 
the National Institutes of Health research laboratory. Inter-labora-
tory variability in JC virus PCR performance is expected to vary, due 
to differences in the platforms, primers, and amplified DNA regions 
used. Thus, as is the case with our patient, low and even negative JC 
virus CSF viral loads may be misleading but do not rule out PML, and 
F I G U R E  6   H&E stained section shows 
a dense inflammatory infiltrate composed 
of T cells (CD3+) and plasma cells 
(CD138+) with only rare B cells (CD20+); 
original magnification ×400
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false-negative results do rarely occur.18 In such situations in which 
CSF testing is negative or equivocal, brain biopsy can be used to 
definitively prove the diagnosis.18 However, despite the low-positive 
initial CSF JC virus PCR in our patient, the clinical and radiographic 
findings were all compatible with PML, obviating the need for a brain 
biopsy during the initial stage of her illness. False-positive JC viral 
loads have been rarely described among patients with multiple scle-
rosis, occurring at rates of 1%-5%.26,27
Immune reconstitution inflammatory syndrome is a severe com-
plication of PML and is characterized by infiltration of the brain with 
activated T cells, resulting in brain edema, mass effect, herniation, 
and death.4,6 PML-IRIS is well described in HIV-infected individuals 
receiving ART,5 as well as in patients with natalizumab-related PML 
after the discontinuation of natalizumab and initiation of plasma-
pheresis.28 In contrast, PML-IRIS after SOT has been infrequently 
reported2 and as demonstrated by our case can be precipitated by 
even a slow taper of immunosuppression. Data on management are 
sparse, and while steroids have been used in HIV-related PML-IRIS, 
their benefit is unproven.28 We were only able to identify two other 
cases evaluating the treatment of PML-IRIS after SOT. In a report of 
a liver transplant recipient, the diagnosis was made based on para-
doxical worsening of the patient's MRI findings after reduction of 
immunosuppression, and the patient survived after a steroid taper.29 
The other patient was a lung transplant recipient whose CD4 count 
increased and MRI findings worsened after reduction of immuno-
suppression. She was treated with mefloquine without steroids, and 
she did not survive.2 Our patient had a favorable outcome after an 
11-week steroid taper.
The diagnosis of PML-IRIS remains challenging. Gadolinium-
enhanced brain MRIs can show enlarged white matter lesions, 
commonly with contrast enhancement due to local inflamma-
tion and breakdown of the blood-brain barrier.3,4 We avoided 
gadolinium in our patient due to her progressively worsening 
renal disease and risk of nephrogenic systemic fibrosis, although 
contemporary data suggest that this risk is low with newer 
gadolinium agents.30 Brain biopsy can reveal characteristic 
pathological findings for both PML and PML-IRIS.4 Given the 
inherent risks of a brain biopsy and our reluctance to pursue 
a contrast-enhanced MRI due to poor renal function,  we per-
formed a thallium SPECT to attempt to differentiate PML from 
PTLD or another neoplastic process. Indeed, the 2013 American 
Academy of Neurology (AAN) consensus recommendations on 
PML diagnostic criteria acknowledge that the presence of in-
creased thallium uptake is typically seen in CNS lymphomas but 
not usually in PML.31 Their recommendations are based on a 
single-center study of eight patients with advanced HIV, six of 
whom had PML and two of whom had primary CNS lymphoma, 
wherein SPECT studies showed lack of uptake among all pa-
tients with PML but intense uptake among both patients with 
lymphoma.9 However, the AAN considers its utility to be lim-
ited, given the widespread use of contrasted MRI imaging and 
the presence of a few false-positive results in the literature.32 
Our patient's thallium SPECT showed avid thallium uptake, 
which may have been confounded by the concomitant presence 
of IRIS. To our knowledge, this is the first report of a thallium 
SPECT scan in a patient with PML-IRIS. Indeed, the literature on 
thallium scans has focused mainly on differentiating PML and 
not PML-IRIS from malignancy, and the performance of thallium 
SPECT in an inflammatory state like PML-IRIS is unknown. We 
hypothesize that the reason for the positive SPECT was because 
at the time it was obtained, the patient had PML-IRIS and not 
simply PML, with lesions in the former expected to be inflamed 
and hypermetabolic, in contrast with lesions in the latter. More 
research is needed to determine the accuracy of thallium SPECT 
as a diagnostic tool for both PML and PML-IRIS, particularly to 
reduce the need of brain biopsies.
In conclusion, PML remains a rare yet nearly universally fatal dis-
order in SOT. Contemporary data are required to define its current 
epidemiology, prognosis and the role of medical therapy, be it re-
duction of immunosuppression or hitherto unproven interventions. 
Large-scale studies of innovative agents such as PD-1 inhibitors and 
adoptive T cell therapy should also include transplant recipients. A 
high index of suspicion for PML-IRIS should be maintained in trans-
plant recipient recipients with paradoxical worsening of their PML 
after reduction in immunosuppression. Characteristic MRI changes 
are suggestive of the diagnosis, while the performance of thallium 
SPECT is largely unknown. A brain biopsy is usually diagnostic. 
Steroids may be lifesaving in cases of CNS IRIS, though data to sup-
port their use are limited.
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